Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers

British Journal of Clinical Pharmacology

Volumn 43, Issue 6, 1997, Pages 563-570

  Cheymol, Georges ^a   Poirier, Jean Marie ^a   Carrupt, Pierre Alain ^b   Testa, Bernard ^b   Weissenburger, Jacques ^a   Levron, Jean Claude ^c,d   Snoeck, Eric ^c,d  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Janssen Research Foundation   (France)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Distribution; Lipophilicity; Obese subjects; Pharmacokinetics; adrenoceptor blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; LABETALOL; NEBIVOLOL; PROPRANOLOL; SOTALOL;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPOPHILICITY; MALE; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TISSUE DISTRIBUTION;

EID: 0030875019     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00609.x     Document Type: Article

References (36)

1. Cheymol G. Clinical pharmacokinetics of drug in obesity, an update. Clin Pharmacokin 1993; 25: 103-114.
2. Abernethy DR. Drug disposition in obese humans. An update. Clin Pharmacokin 1986; 11: 199-213.
3. Poirier JM, Le Jeune C, Cheymol G, Cohen A, Barré J, Hugues FC. Comparison of propranolol and sotalol pharmacokinetics in obese subjects. J Pharm Pharmacol 1990; 42: 344-348.
4. Cheymol G, Poirier JM, Barré J, Pradalier A, Dry J. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol 1987; 27: 874-879.
5. Le Jeune C, Poirier JM, Cheymol G, Ertzbischoff O, Engel F, Hugues FC. Pharmacokinetics of i. v. bisoprolol in obese and non obese volunteers. Eur J Clin Pharmacol 1991; 41: 171-174.
6. Goa KL, Benfield P, Sarkin EM. Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs 1989; 37: 583-627.
7. McLay JS, Irvine N, McDevitt DG. Clinical pharmacology of nebivolol. Drug Investig 1991, 3, (Suppl. 1): 31-32.
8. Anonymous. Weights of insured persons in the United States associated with lowest mortality. Stat Bull Metrop Insur 1989, Co40 November-December.
9. Hinderliter AL, Fitzpatrick MA, Shork N, Julius S. Research utility of non-invasive methods for measurement of cardiac output. Clin Pharmacol Ther 1987; 41: 419-425.
10. Lo M, Silber B, Riegelman S. An automated h.p.l.c. method for the assay of propranolol and its basic metabolites in plasma and urine. J Chromatogr 1982; 20: 126-131.
11. Woestenborghs R, Embrechts L, Heykants J. HPLC-fluorescence method for the determination of a new β1 adrenoreceptor blocking agent nebivolol in human plasma. In: Methodological Surveys in Biochemistry and Analysis, eds. Reid E, Wilson ID, New York: Plenum Press 1988; Vol 18: 215-216.
12. Meredith PA, McSharry D, Elliot HL, Reid JL. The determination of labetalol in plasma by high-performance liquid chromatography using fluorescence detection. J Pharmacol Methods 1981; 6: 309-314.
13. Van Peer A, Snoeck E, Woestenborghs CR, et al. Clinical pharmacokinetics of nebivolol. A review. Drug Investig 1991; 3 (Suppl. 1): 25-30.
14. Hildebrand M, Seifert W, Reichenberger A. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 1989; 36: 315-318.
15. Gomeni R. Pharm: an interactive graphic program for individual and population pharmacokinetic parameter population. Comp Biol Med 1984; 14: 25-34.
16. Avdeef A. pH-metric log P. Part 1. Difference plots for determining ion-pair octanol-water partition coefficients of multiprotic substances. Quant Struct - Act Relat 1992; 11: 510-517.
17. Avdeef A. pH-metric log P. II. Refinement of partition coefficients and ionization constants of multiprotic substances. J Pharm Sci 1993; 82: 1-8.
18. Tsai RS, Carrupt PA, Testa B. Measurement of partition coefficients using centrifugal partition chromatography: method development and application to the determination of solute structural properties. In ACS Symposium Series no. 593. Modeen contercurrent Chromatography, Conway, WD, Petroski, PJ Eds.; American Chemical Society, Washington, DC, USA: 1995: 143-154
19. Vallat P, Gaillard P, Carrupt PA, Tsai RS, Testa B. Structure-lipophilicity and structure-polarity relationships of amino acids and peptides. Helv Chim Acta 1995; 78: 471-485.
20. Yasuda M. Dissociation constants of some carboxylic acids in mixed aqueous solvents. Bull Chem Soc Jpn 1959; 32: 429-432.
21. Barbato F, Caliendo G, La Rotonda MI, Morrica P, Silipo C, Vittoria A. Relationships beetween octanol-water partition data, Chromatographic indices and their dependence on pH in a set of β-adrenoceptor blocking agents. II Farmaco 1990; 45: 647-663.
22. Recanatini M. Partition and distribution coefficients of aryloxypropanolamine β-adrenoceptor antagonists. J Pharm Pharmacol 1992; 44: 68-70.
23. Richard DA, Prichard BNC, Dobbs RJ. Adrenoceptor blockade of the circulatory responses to intravenous isoproterenol. Clin Pharmacol Ther 1978; 24: 264-273.
24. Man In't Veld AJ, Schalekamp MADH. How intrinsic sympathomimetic activity modulates the haemodynamic responses to β-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol 1982; 13 (Suppl 2): 245S-257S.
25. Van Rooy P, Van Nueten L, De Cree J. Blood pressure reduction in relation to β-blockade in healthy volunteers. Drug Investig 1991; 3 (Suppl. 1): 174-175.
26. Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 1979; 7: 49-54.
27. Bowman SL, Hudson SA, Simpson G, et al. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol 1986; 21: 529-537.
28. Elliott HL, Meredith PA, Summer DJ, Reid JL. Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. Br J Clin Pharmacol 1984; 17: 573-578.
29. Abernethy DR, Schwartz JB, Plachetka J, et al. Pharmacodynamics and disposition of labetalol in elderly hypertensive patient. J Clin Pharmacol 1985; 25: 468.
30. Forbes GB, Weile SL. Lean body mass in obesity. Intern J Obesity 1983; 7: 99-107.
31. Womersley J, Durning JVGA, Boddy K, Mahaffy M. Influence of muscular development, obesity and age on the fat-free mass of adults. J Appl Physiol 1976; 47: 223-229
32. Testa B, El Tayar N, Altomare C, Carrupt PA, Tsai RS. Lipophilicity and hydrogen bonding capacity: their role in drug binding and disposition. In Proceedings of the International Symposium on blood binding and drug transfer. Éditions Fort et Clair Paris, 1993: 109-120.
33. El Tayar N, Tsai RS, Testa B, Carrupt PA, LEO A. Partitioning of solutes in different solvent systems: the contribution of hydrogen-bonding capacity and polarity. J Pharm Sci 1991; 80: 590-598.
34. El Tayar N, Testa B, Carrupt PA. Polar interactions encoded in partition coefficients: An indirect estimation of hydrogen-bond parameters of polyfunctional solutes. J Physic Chem 1992; 96: 1455-1459.
35. El Tayar N, Tsai RS, Testa B, Carrupt PA, Hansch C, Leo A. Percutaneous penetration of drugs: A quantitative structure-permeation relationship study. J Pharm Sci 1991; 80: 744-749.
36. BickeL MH. Factors affecting the storage of drugs and other xenobiotics in adipose tissue. In Advances in Drug Research, Vol. 25, eds Testa B, Meyer UA, Academic Press, London, 1994: 55-86.